Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis
详细信息 查看全文
- 作者：Jeffrey V Lazarus (44)
Jens Lundgren (44)
Jordi Casabona (45)
Lucas Wiessing (46)
Catharina Mathe茂 (47)
Peter Vickerman (48) (49)
Maria Prins (50) (51)
Mirjam Kretzschmar (52) (53)
Maria Kantzanou (54)
Isabelle Giraudon (46)
Marica Ferri (46)
Paul Griffiths (46)
Magdalena Harris (55)
Margaret Walker (56)
Lilyana Chavdarova (56)
Eberhard Schatz (57)
Katrin Schiffer (57)
John Peter Kools (57)
Jason Farell (57)
Lu铆s Mend茫o (58) (59) - 刊名：BMC Infectious Diseases
- 出版年：2014
- 出版时间：September 2014
- 年：2014
- 卷：14
- 期：6-supp
- 全文大小：286 KB
- 参考文献：1. Mocroft A, Lundgren JD, Sabin M, / et al.: Risk Factors and Outcomes for Late Presentation for HIV-positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). / PLoS Med 2013, 10:9. CrossRef
2. HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. Working Group on Estimation of HIV Prevalence in Europe / AIDS 2011,25(8):1017鈥?3. doi: 10.1097/QAD.0b013e3283467087
3. Sullivan A, Raben D, Reekie J, / et al.: Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES 1 (HIV Indicator Diseases across Europe Study). / PlosOne 2013, 8:1.
4. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, / et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. / Nature 2009, 461:798鈥?01. CrossRef
5. Lavanchy D: Evolving epidemiology of hepatitis C virus. / Clin Microbiol Infect 2011, 17:107鈥?15. CrossRef
6. World Health Organisation. Hepatitis C - Fact sheet N掳164. 2014
7. Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M, Cowan SA: European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs) - the need to improve quality and comparability. / Euro Surveill 2008, 13:pii=18884.
8. Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. / Epidemiol Infect 2014, 142:270鈥?86. CrossRef
9. Bravo MJ, Vallejo F, Barrio G, Brugal MT, Molist G, Pulido J, / et al.: HCV seroconversion among never-injecting heroin users at baseline: no predictors identified other than starting injection. / Int J Drug Policy 2012, 23:415鈥?19. CrossRef
10. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Boothe R, Abdool R, / et al.: HIV and risk environment for injecting drug users: the past, present, and future. / Lancet 2010, 376:268鈥?84. CrossRef
11. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen K, / et al.: Hepatitis C virus infection epidemiology among people who inject drugs in Europe 鈥?A systematic review of data for scaling up treatment and prevention. / Plos One 2014,9(7):e103345. doi: 10.1371/journal.pone.0103345 CrossRef
12. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J: Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. / Euro Surveill 2011, 16:pii=20031.
13. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2014 / Lisbon, EMCDDA 2014.
14. Wiessing L, Likatavicius G, Klempova D, Hedrich D, Nardone A, Griffiths P: Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. / Am J Public Health 2009, 99:1049鈥?052. CrossRef
15. Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L: Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. / Addiction 2010, 105:311鈥?18. CrossRef
16. Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, / et al.: Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? / Drug Alcohol Depend 2013, 132:172鈥?81. CrossRef
17. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, / et al.: Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. / Euro Surveill 2011, 16:pii=20032.
18. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, / et al.: Human immunodeficiency virus among people who inject drugs: Is risk increasing in Europe? / Euro Surveill 2013, 18:pii=20648.
19. Kretzschmar M, Wiessing L: New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users. / AIDS 2008, 22:1527鈥?537. CrossRef
20. Kretzschmar M, Wiessing L: Coordination of a working group to develop mathematical and statistical models and analyses of protective factors for HIV infection among injecting drug users. / 2007. Report. Lisbon, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2007.
21. Grebely J, Dore G: Can hepatitis C virus infection be eradicated in people who inject drugs? / Antiviral Research 2014, 104:62鈥?2. CrossRef
22. Nguyen V-K, Bajos N, Dubois-Arber , / et al.: Remedicalising an epidemic: from HIV treatment as prevention to HIV treatment is prevention. / AIDS 2011,25(3):291鈥?. CrossRef - 作者单位：Jeffrey V Lazarus (44)
Jens Lundgren (44)
Jordi Casabona (45)
Lucas Wiessing (46)
Catharina Mathe茂 (47)
Peter Vickerman (48) (49)
Maria Prins (50) (51)
Mirjam Kretzschmar (52) (53)
Maria Kantzanou (54)
Isabelle Giraudon (46)
Marica Ferri (46)
Paul Griffiths (46)
Magdalena Harris (55)
Margaret Walker (56)
Lilyana Chavdarova (56)
Eberhard Schatz (57)
Katrin Schiffer (57)
John Peter Kools (57)
Jason Farell (57)
Lu铆s Mend茫o (58) (59)
44. CHIP, Centre for Health and Infectious Disease Research and WHO Collaborating Centre on HIV and Viral Hepatitis, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
45. Epidemiological Center for HIV/AIDS/STI of Catalonia (CEEISCAT), Barcelona, Spain
46. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal
47. Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
48. London School of Hygiene and Tropical Medicine (LSHTM), London, UK
49. School of Social and Community Medicine, University of Bristol, Bristol, UK
50. Cluster Infectious Diseases, Department of Research, Public Health Service, Amsterdam, the Netherlands
51. Center for Infection and Immunity (CINIMA), Academic Medical Center, Amsterdam, the Netherlands
52. Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands
53. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
54. National Reference Centre for Retroviruses, Laboratory of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
55. London School of Hygiene and Tropical Medicine (LSHTM), London, UK
56. European Liver Patients鈥?Associaton, B-3800, Sint-Truiden, Belgium
57. Correlation 鈥?European Network Social Inclusion and Health, Amsterdam, the Netherlands
58. G.A.T. 鈥?Grupo Portugu锚s de Activistas sobre Tratamentos de VIH/SIDA, Pedro Santos, Portugal
59. European AIDS Treatment Group, B-1050, Brussels, Belgium - ISSN：1471-2334
文摘